Oncothyreon and Celldex Therapeutics Announce Collaboration for Combination Immunotherapy Clinical Trial of ONT-10 and Varlilumab

May 29, 2014 Oncothyreon Inc. and Celldex Therapeutics, Inc., today announced that they have agreed to collaborate on a combined clinical trial of ONT-10 and varlilumab. ONT-10 is a therapeutic vaccine targeting the tumor-associated antigen MUC1. Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes. The planned trial is an …